Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Testing of putative antiseizure medications in a preclinical Dravet syndrome zebrafish model

1 Jan 2024

Abstract excerpt

Abstract Dravet syndrome is a severe genetic epilepsy primarily caused by de novo mutations in a voltage-activated sodium channel gene (SCN1A). Patients face life-threatening seizures that are largely resistant to available anti-seizure medications. Preclinical Dravet syndrome animal models are a valuable tool to identify candidate anti-seizure medications for these patients. Among these, scn1lab mutant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epilepsy research and treatment
Share to Neuroscience and Neuropharmacology Research
Share to Zebrafish Biomedical Research Applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38707709
DOI: 10.1093/braincomms/fcae135

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Testing of putative antiseizure medications in a preclinical Dravet syndrome zebrafish modelPMID 38707709Read ↗

Testing of putative antiseizure drugs in a preclinical Dravet syndrome zebrafish modelSemantic proximity Read ↗

Clemizole and Trazodone are Effective Antiseizure Treatments in a Zebrafish Model of STXBP1 DisorderSemantic proximity Read ↗

Drug repurposing for Dravet syndrome in scn1Lab−/− mutant zebrafishSemantic proximity Read ↗

Phenotype-Based Screening of Synthetic Cannabinoids in a Dravet Syndrome Zebrafish ModelSemantic proximity Read ↗

Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment.Semantic proximity Read ↗

Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndromeSemantic proximity Read ↗

Phenotype-based screening of synthetic cannabinoids in a Dravet Syndrome zebrafish modelSemantic proximity Read ↗

Pharmacological Characterization of an Antisense Knockdown Zebrafish Model of Dravet Syndrome: Inhibition of Epileptic Seizures by the Serotonin Agonist FenfluramineSemantic proximity Read ↗

Development of an Antiseizure Drug Screening Platform for Dravet Syndrome at the NINDS contract site for the Epilepsy Therapy Screening ProgramSemantic proximity Read ↗

Toward the use of novel alternative methods in epilepsy modeling and drug discoverySemantic proximity Read ↗

Behavioral Comorbidities and Drug Treatments in a Zebrafish scn1lab Model of Dravet Syndrome.Semantic proximity Read ↗

Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet SyndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.